Health brief
Oral GLP-1 Weight-Loss Launch and NHS Dental Care Crisis
Eli Lilly debuts Europe's first oral GLP-1 weight-loss pill in UK pharmacies while Nuffield Trust figures reveal 10% of English dental practices quit NHS care.
Health
Eli Lilly launched its daily weight-loss pill in UK pharmacies — making Britain Europe's first market for oral GLP-1s and testing patient demand for non-injectable options.
BackgroundGLP-1 receptor agonists have transformed weight management treatment, but existing therapies require weekly subcutaneous injections. Oral formulations eliminate injection requirements, though manufacturing challenges have previously limited widespread pharmaceutical availability.
- The MHRA approved Foundayo without restrictions on food or liquid intake, allowing patients flexibility compared to earlier oral peptide formulations.
- Eli Lilly is working with NICE on clinical cost-effectiveness assessments, setting up potential NHS prescription availability across England in coming years.
- Community pharmacists welcomed the oral option for needle-phobic patients, but warned consumers against purchasing unverified versions from unregulated online outlets.
- Private prescription costs are expected to match monthly pricing structures established for weekly injectable weight-loss treatments, preserving high patient demand.
Health
Nuffield Trust data showed 1 in 10 English dental practices quit state care since 2017 — exposing how fee contracts are dismantling universal NHS dentistry.
BackgroundNHS dental providers in England operate under a fee-per-treatment contract that dentists argue fails to cover basic operational costs. Low funding levels have prompted thousands of practitioners to reduce or abandon NHS commitments in favor of private practice.
- The NHS lost 600 dental practices providing general state care across England between 2017 and 2026, creating vast regional care deserts.
- The proportion of English practices offering NHS treatment dropped from 65% in 2017 down to 56% in 2026, leaving public options in the minority.
- 41 out of 42 Integrated Care Boards recorded losses, with the South West seeing the steepest fall in available state-funded dentists.
- The British Dental Association urged the Department of Health to overhaul the contract structure before public dentistry collapses entirely across high-deprivation areas.
Health
A Royal Brompton Hospital trial showed an implant relieved severe pain in 75% of untreatable heart patients — establishing a therapeutic path for refractory angina.
BackgroundRefractory angina occurs when severe chest pain persists despite maximal medical therapy or prior bypass surgery. Patients with no further surgical options experience severe mobility limitations and frequent hospital admissions due to chronic chest pain.
- The coronary sinus reducer mesh implant altered heart muscle blood flow to relieve chest pain in 75% of trial patients, enabling greater mobility.
- Patients reported dramatic reductions in weekly angina attacks, cutting emergency hospital admissions and reliance on high-dose pain medications.
- Lead cardiologist Dr Ranil de Silva noted the outpatient procedure provides a low-risk intervention for conditions previously deemed untreatable.
- Broader clinical trials are underway to support formal NICE evaluation, which could establish standardized funding across NHS cardiac centres.
Health
Belfast researchers developed a 3D-printed dissolvable patch for targeted skin cancer therapy — proving additive manufacturing can streamline non-invasive drug delivery.
BackgroundTopical chemotherapy creams often struggle to penetrate deep skin layers, while systemic injections can cause widespread organ toxicity. Microneedle patches bypass outer skin barriers to deliver concentrated medication directly to localized tumor sites.
- Belfast researchers used a single-step 3D printing process to mix anti-cancer therapeutics into dissolvable microneedle resin, simplifying manufacturing.
- The patch dissolves upon contact with skin moisture, delivering a sustained release of two anti-cancer drugs directly into localized tumor tissue.
- Painless application eliminates needle phobia while preventing accidental needle-stick injuries among healthcare workers administering targeted oncology treatments.
- Lead researcher Prof Dimitrios Lamprou noted the customisable printing process cuts medical waste while improving patient compliance during outpatient care.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
